PF-Atlas › Clinical Trials › NCT05571059
Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis
Ifetroban Sodium · Phase 2
Registry ID
NCT05571059
Phase
Phase 2
Status
Recruiting
Drug / intervention
Ifetroban Sodium
Sponsor
Cumberland Pharmaceuticals
Start
2024-01-31
Enrollment
128
Locations
19
About this trial
Ifetroban prevents and treats lung fibrosis due to multiple causes (bleomycin, genetic, radiation). The safety and efficacy of oral ifetroban will be assessed in patients with IPF.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT05571059 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.